Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy

Inclusion criteria : * Patients with age between 18 and 70 years. * Hemoglobin A1c\>7.5%, and ≤11%. * Fasting plasma glucose \>7 mmol/L. * Fasting C peptide \>1 ng/mL. * Type 2 diabetes (T2DM) patients with diabetes diagnosis between 2 and 10 years (World Health Organization 1999 T2DM diagnose criteria). * Continuous treatment with stable doses of metformin (≥1 g/day) and 1 oral antihyperglycemic drug (at least half maximum dose) for more than 3 months prior to screening. * Body mass index ≥21 kg/m2, and \<40 kg/m2. Exclusion criteria: * More than 7 consecutive days of insulin treatment within the 12 months except for acute disease or surgery. * Diabetes other than T2DM (e.g. type 1 diabetes, diabetes secondary to pancreatic disorders, drug or chemical agent intake). * History of hypoglycemia unawareness or recurrent hypoglycemia or severe hypoglycemia within the past 12 months. * History of sensitivity to the study drugs or to drugs with a similar chemical structure. * Pregnancy or planned pregnancy or current lactation (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraception method). * Acute diabetic complications (diabetic ketoacidosis, lactic acidosis, hyperosmolar nonketotic diabetic coma) within the past 12 months. * Significant diabetic complications and serious disease, e.g., symptomatic autonomic neuropathy, gastroparesis, unstable angina or active proliferative retinopathy. * Acute infections which may affect BG control within the past 4 weeks. * Active liver disease, alanine transaminase (ALT) and/or aspartate aminotransferase (AST) greater than two times the upper limit of the reference range at screening. * Impaired renal function, defined as but not limited to, serum creatinine levels ≥1.5 mg/dL (132 μmol/L) for males and ≥1.4 mg/dL (123 μmol/L) for females or presence of macroproteinuria (\>2 g/day). The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.